The US Food and Drug Administration on Monday approved the use of the experimental drug aducanumab for early phases of Alzheimer's disease -- despite an FDA advisory committee concluding last year ...
At its November meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) voted against Biogen's controversial Alzheimer's drug aducanumab (Aduhelm), ...
A biotechnology company’s plans to file for Food and Drug Administration approval of a drug to treat Alzheimer’s disease despite ending its clinical trial program following a futility analysis have ...
One such type of medication is called anti-amyloid monoclonal antibodies. Previous studies show these medications — which currently include aducanumab, lecanemab, and donanemab — can help reduce ...
Nov 3 (Reuters) - U.S. health experts this week will decide whether to recommend approval for Biogen Inc's (BIIB.O), opens new tab Alzheimer's drug, which could become the first new treatment for the ...
CAMBRIDGE, Mass. -- Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of ...
“We are encouraged by these new results, which continue to show that treatment of prodromal and mild Alzheimer’s disease patients with aducanumab resulted in a statistically significant, ...
Standard effect sizes are more meaningful outcomes in Alzheimer's disease drug trials than the widely used metric of percent slowing of decline, an analysis suggested. In recent trials of Alzheimer's ...
Yesterday, the Food and Drug Administration (FDA) approved aducanumab as a treatment for Alzheimer's. This was history-making, as it was the first medication approved to treat Alzheimer's since 2003.
Alzheimer's disease poses a significant therapeutic challenge due to the restrictive nature of the blood-brain barrier (BBB) hindering the delivery of therapeutic agents to the brain tissue. To ...
When it comes to Alzheimer's, there are many elephants in the room Source: redcharlie/Unsplash This is a guest post by Cameron J. Camp, Ph.D., Director of Research and Development, Center for Applied ...
CAMBRIDGE, Mass. -- Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback